GlassScriptPhysician profile
Rufus C Davis
NPI 1649267501
$13,860.85
in general payments reported to CMS, 2019-2025
40 companies · $2,881 in 2025
The $2,881 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $509 · 2021: $1,447 · 2022: $2,462 · 2023: $2,566 · 2024: $2,692 · 2025: $2,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,138.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,996.20 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,715.39 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,397.82 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,187.67 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $755.93 | 2022-2025 | |
| Celgene Corporation | $573.58 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $504.94 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $281.79 | 2020-2025 | |
| Ardelyx, INC. | $266.62 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $246.87 | 2020-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $208.56 | 2019-2025 | |
| Braintree Laboratories, INC. | $164.83 | 2019-2024 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $127.92 | 2024-2025 | Voquezna |
| Allergan, INC. | $125.42 | 2019 | |
| Madrigal Pharmaceuticals | $123.67 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rufus Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.